| Parameter | ADA (no Uveitis) (n=12) | ADA (Uveitis) (n=13) | ETA (no Uveitis) (n=49) | P between ADA (no Uveitis) and ADA (Uveitis) | P between ADA (no Uveitis) and ETA (no Uveitis) | P between ADA (Uveitis) and ETA (no Uveitis) |
|---|---|---|---|---|---|---|
| Females, n (%) | 6 (50%) | 8 (61.54%) | 41 (83.67%) | 0.859 | 0.035 | 0.174 |
| Active uveitis at the start of treatment, n (%) | 0 (0%) | 13 (100%) | 0 (0%) | <0.001 | – | <0.001 |
| Diagnosis | – | – | – | – | – | – |
| extended oligoarthritis, n (%) | 0 (0%) | 2 (15.38%) | 7 (14.29%) | 0.706 | 0.011 | 0.225 |
| persistent oligoarthritis, n (%) | 5 (41.67%) | 6 (46.15%) | 32 (65.31%) | |||
| RF- polyarthritis, n (%) | 5 (41.67%) | 4 (30.77%) | 10 (20.41%) | |||
| psoriatic arthritis, n (%) | 2 (16.67%) | 1 (7.69%) | 0 (0%) | |||
| Age at disease onset, median (IQR), years | 2.25 (1.38: 3.08) | 2 (1.5: 2.9) | 1.8 (1.4: 2.2) | 0,7 | 0,283 | 0.258 |
| Age at start of current therapy (ETA/ADA), median (IQR), years | 3.9 (3.1: 4) | 3.7 (3.4: 3.9) | 2.8 (2: 3) | 0.56 | <0.001 | 0.003 |
| JIA duration before start ETA/ADA, median (IQR), years |
1 (0.57: 1.7) | 1.1 (0.9: 2) | 0.6 (0.4: 1) | 0.682 | 0.054 | 0.012 |
| Prior therapy with biologics, n (%) | 4 (33.3%) | 4 (30.8%) | 2 (4.1%) | >0.999 | 0.011 | 0.015 |
| Prior therapy with methotrexate, n (%) | 11 (91.7%) | 13 (100%) | 31 (63.3%) | >0.999 | 0.083 | 0.013 |